WallStSmart

AstraZeneca PLC (AZN)vsTactile Systems Technology Inc (TCMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 17417% more annual revenue ($61.37B vs $350.31M). AZN leads profitability with a 17.0% profit margin vs 7.1%. AZN appears more attractively valued with a PEG of 1.28. AZN earns a higher WallStSmart Score of 60/100 (C+).

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

TCMD

Buy

56

out of 100

Grade: C

Growth: 8.0Profit: 5.5Value: 4.3Quality: 9.0
Piotroski: 5/9Altman Z: 4.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+18.4%)

Margin of Safety

+18.4%

Fair Value

$196.10

Current Price

$160.17

$35.93 discount

UndervaluedFair: $196.10Overvalued

Intrinsic value data unavailable for TCMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$252.33B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

TCMD4 strengths · Avg: 9.5/10
EPS GrowthGrowth
144.1%10/10

Earnings expanding 144.1% YoY

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.8010/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Areas to Watch

AZN2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

TCMD3 concerns · Avg: 2.7/10
Market CapQuality
$495.41M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
7.1%3/10

7.1% margin — thin

PEG RatioValuation
17.792/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bull Case : TCMD

The strongest argument for TCMD centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bear Case : AZN

The primary concerns for AZN are EPS Growth, Altman Z-Score.

Bear Case : TCMD

The primary concerns for TCMD are Market Cap, Profit Margin, PEG Ratio.

Key Dynamics to Monitor

AZN profiles as a mature stock while TCMD is a value play — different risk/reward profiles.

TCMD carries more volatility with a beta of 0.79 — expect wider price swings.

TCMD is growing revenue faster at 8.6% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (60/100 vs 56/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Tactile Systems Technology Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.

Want to dig deeper into these stocks?